论文部分内容阅读
本文初步观察10组病例应用放射免疫分析尿中TXB_2和6-Keto-PGF_(1α)浓度变化,在临床疾病中的意义。结果表明,正常人对照组测定浓度TXB_2为191.9±23.6pg/min,6-keto—PGF_(1α)为为511.0±82.6pg/min(X±SEn=14)。尿毒症患者尿中TXB_2为45.5±8.5pg/min,6-Keto-PGF_(1α)39.8±16.1pg/min(X±SEn=12)。与对照组统计学分析比较相差非常显著P<0.01。其余各组尿中TXB_2测值较对照组有不同幅度升高,统计学分析相差显著P<0.05或相差非常显著P<0.01。6-Keto-PGF_(1α)测值随病情程度或不同疾病其变化不同。
This article preliminary observation of 10 groups of patients using radioimmunoassay urinary TXB_2 and 6-Keto-PGF_ (1α) concentration changes in clinical disease significance. The results showed that the concentration of TXB_2 in control group was 191.9 ± 23.6 pg / min and that of 6-keto-PGF_ (1α) was 511.0 ± 82.6 pg / min (X ± SEn = 14). Urinary TXB_2 in uremic patients was 45.5 ± 8.5 pg / min and 6-Keto-PGF_ (1α) 39.8 ± 16.1 pg / min (X ± SEn = 12). Compared with the control group statistically significant difference P <0.01. The remaining groups of urine TXB_2 measured values ?? compared with the control group increased in different amplitudes, statistical analysis was significantly different P <0.05 or significant difference P <0.01.6-Keto-PGF_ (1α) measured with the severity or different diseases Different changes.